I uge 8 i monoterapi med VIRAMUNE havde 100% af de testede patienter HIV- isolater med en > 100 gange mindre følsomhed overfor nevirapin uanset dosis.
By week 8 of VIRAMUNE monotherapy, 100% of the patients tested had HIV isolates with a > 100-fold decrease in susceptibility to nevirapine, regardless of dose.